Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?

Topics: Breast Cancer • Radiation Oncology • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • HR+ • NCI-CCC Breast Tumor Board Question

Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib (near primary tumor but not clearly direct extension) and good response to 6 months of AI+CDK4i

Answer from: Medical Oncologist at Academic Institution

The description of "ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligo-metastatic disease in the right 4th rib (near primary tumor but not clearly direct extension) and good response to 6 months of AI+CDK4i" suggests that the primary breast cancer is intact. The...

Comments

Medical Oncologist at Loyola University Chicago Stritch School of Medicine
See also recent updates to relevant discussion fro...

Answer from: Radiation Oncologist at Community Practice

Agree with @Amye Tevaarwerk, we approach in the same manner in ER+/HER2- breast patients with favorable response on systemic therapy -- don't offer SBRT with good response on systemic therapy. In the setting of true oligoprogression in ER+/HER2- tumors at primary site or at known met while on...

Comments

Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital
Dr. @Arscott, Would this be your approach for a p...

Radiation Oncologist at Compass Oncology
If enhancement properties and peritumoral edema/T2...

Related Questions